|
1
|
Saluja A and Maitra A: Pancreatitis and
pancreatic cancer. Gastroenterology. 156:1937–1940. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neoptolemos JP, Kleeff J, Michl P,
Costello E, Greenhalf W and Palmer DH: Therapeutic developments in
pancreatic cancer: Current and future perspectives. Nat Rev
Gastroenterol Hepatol. 15:333–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuoka T and Yashiro M: Molecular
targets for the treatment of pancreatic cancer: Clinical and
experimental studies. World J Gastroenterol. 22:776–789. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rozenblum E, Schutte M, Goggins M, Hahn
SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeoet CJ,
et al: Tumor-suppressive pathways in pancreatic carcinoma. Cancer
Res. 57:1731–1734. 1997.PubMed/NCBI
|
|
7
|
Yashiro M, Carethers JM, Laghi L, Saito K,
Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K and Boland
CR: Genetic pathways in the evolution of morphologically distinct
colorectal neoplasms. Cancer Res. 61:2676–2683. 2001.PubMed/NCBI
|
|
8
|
Moskaluk CA, Hruban RH and Kern SE: p16
and K-ras gene mutations in the intraductal precursors of human
pancreatic adenocarcinoma. Cancer Res. 57:2140–2143.
1997.PubMed/NCBI
|
|
9
|
Hruban RH, van Mansfeld AD, Offerhaus GJ,
van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK,
Cameron JL and Bos JL: K-ras oncogene activation in adenocarcinoma
of the human pancreas. A study of 82 carcinomas using a combination
of mutant-enriched polymerase chain reaction analysis and
allele-specific oligonucleotide hybridization. Am J Pathol.
143:545–554. 1993.PubMed/NCBI
|
|
10
|
Kosmidis C, Sapalidis K, Kotidis E,
Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG and
Kanellos J: Pancreatic cancer from bench to bedside: Molecular
pathways and treatment options. Ann Transl Med. 4:1652016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bryant KL, Mancias JD, Kimmelman AC and
Der CJ: KRAS: Feeding pancreatic cancer proliferation. Trends
Biochem Sci. 39:91–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prabhu L, Mundade R, Korc M, Loehrer PJ
and Lu T: Critical role of NF-κB in pancreatic cancer. Oncotarget.
5:10969–10975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Abbruzzese JL, Evans DB, Larry L,
Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA
transcription factor is constitutively activated in human
pancreatic adenocarcinoma cells. Clin Cancer Res. 5:119–127.
1999.PubMed/NCBI
|
|
14
|
Fujioka S, Sclabas GM, Schmidt C,
Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao
PJ: Function of nuclear factor kappaB in pancreatic cancer
metastasis. Clin Cancer Res. 9:346–354. 2003.PubMed/NCBI
|
|
15
|
Mo W, Chen J, Patel A, Zhang L, Chau V, Li
YJ, Cho WS, Lim K, Xu J, Lazar AJ, et al: CXCR4/CXCL12 mediate
autocrine cell-cycle progression in NF1-associated malignant
peripheral nerve sheath tumors. Cell. 152:1077–1090. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 4:a0000342009.PubMed/NCBI
|
|
17
|
Karandish F and Mallik S: Biomarkers and
targeted therapy in pancreatic cancer. Biomarkers Cancer. 8 (Suppl
1):S27–S35. 2016.PubMed/NCBI
|
|
18
|
Takahashi H, Funahashi H, Sawai H, Matsuo
Y, Yamamoto M, Okada Y, Takeyama H and Manabe T: Synthetic serine
protease inhibitor, gabexate mesilate, prevents nuclear
factor-kappaB activation and increases TNF-alpha-mediated apoptosis
in human pancreatic cancer cells. Dig Dis Sci. 52:2646–2652. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhuang Z, Ju HQ, Aguilar M, Gocho T, Li H,
Iida T, Lee H, Fan X, Zhou H, Ling J, et al: IL1 receptor
antagonist inhibits pancreatic cancer growth by abrogating NF-κB
activation. Clin Cancer Res. 22:1432–1444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun YL, Wu CS, Ma JX, Yang Y, Man XH, Wu
HY and Li SD: Toll-like receptor 4 promotes angiogenesis in
pancreatic cancer via PI3K/AKT signaling. Exp Cell Res.
347:274–282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niu J, Li Z, Peng B and Chiao PJ:
Identification of an autoregulatory feedback pathway involving
interleukin-1a in induction of constitutive NF-kappaB activation in
pancreatic cancer cells. J Biol Chem. 279:16452–16462. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ling JH, Kang Y, Zhao RY, Xia QH, Lee DF,
Chang Z, Li J, Peng BL, Fleming JB, Wang HM, et al:
KrasG12D-Induced IKK2/β/NF-κB activation by IL-1α and p62
feedforward loops is required for development of pancreatic ductal
adenocarcinoma. Cancer Cell. 21:105–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang DX, Li L, Jiang HM, Knolhoff BL,
Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB and Lim KH:
Constitutive IRAK4 activation underlies poor prognosis and
chemoresistance in pancreatic ductal adenocarcinoma. Clin Cancer
Res. 23:1748–1759. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salcedo R, Cataisson C, Hasan U, Yuspa SH
and Trinchieri G: MyD88 and its divergent toll in carcinogenesis.
Trends Immunol. 34:232–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang B, Chen R, Wang T, Cao L, Liu Y, Yin
F, Zhu M, Fan X, Liang Y, Zhang L, et al: Myeloid differentiation
Factor 88 promotes growth and metastasis of human hepatocellular
carcinoma. Clin Cancer Res. 19:2905–2915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu XX, Burfeind KG, Michaelis KA, Braun
TP, Olson B, Pelz KR, Morgan TK and Marks DL: MyD88 signalling is
critical in the development of pancreatic cancer cachexia. J
Cachexia Sarcopeni. 10:378–390. 2019. View Article : Google Scholar
|
|
28
|
Loiarro M, Capolunghi F, Fantò N, Gallo G,
Campo S, Arseni B, Carsetti R, Carminati P, Santis RD, Ruggiero V,
et al: Pivotal advance: Inhibition of MyD88 dimerization and
recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
J Leukoc Biol. 82:801–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng Y, Sun J and Zhang LD: Effect of
ST2825 on the proliferation and apoptosis of human hepatocellular
carcinoma cells. Genet Mol Res. 15:150168262016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Tassell BW, Seropian IM, Toldo S,
Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V and
Abbate A: Pharmacologic inhibition of myeloid differentiation
factor 88 (MyD88) prevents left ventricular dilation and
hypertrophy after experimental acute myocardial infarction in the
mouse. J Cardiovasc Pharmacol. 55:385–390. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang S, Li F, Li X, Wang L, Zhang L, Lu
C, Zheng L and Yan M: Transcriptome analysis of PK-15 cells in
innate immune response to porcine deltacoronavirus infection. PLoS
One. 14:e02231772019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinaldi L, Delle DR, Catalanotti B,
Torres-Quesada O, Enzler F, Moraca F, Nisticò R, Chiuso F, Piccinin
S, Bachmann V, et al: Feedback inhibition of cAMP effector
signaling by a chaperone-assisted ubiquitin system. Nat Commun.
10:25722019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu D, Li L, Zhang XX, Wan DY, Xi BX, Hu
Z, Ding WC, Zhu D, Wang XL, Wang W, et al: SIX1 promotes tumor
lymphangiogenesis by coordinating TGFβ signals that increase
expression of VEGF-C. Cancer Res. 74:5597–5607. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ignacio RMC, Dong YL, Kabir SM, Choi H,
Lee E, Wilson AJ, Beeghly-Fadiel A, Whalen MM and Son D: CXCR2 is a
negative regulator of p21 in p53-dependent and independent manner
via Akt-mediated Mdm2 in ovarian cancer. Oncotarget. 9:9751–9765.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mittal D, Saccheri F, Vénéreau E, Pusterla
T, Bianchi ME and Rescigno M: TLR4-mediated skin carcinogenesis is
dependent on immune and radioresistant cells. EMBO J. 29:2242–2252.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rakoff-Nahoum S and Medzhitov R:
Regulation of spontaneous intestinal tumorigenesis through the
adaptor protein MyD88. Science. 317:124–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fathallah I, Parroche P, Gruffat H,
Zannetti C, Johansson H, Yue J, Manet E, Tommasino M, Sylla BS and
Hasan UA: EBV latent membrane protein 1 is a negative regulator of
TLR9. J Immunol. 185:6439–6447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Coste I, Le Corf K, Kfoury A, Hmitou I,
Druillennec S, Hainaut P, Eychene A, Lebecque S and Renno T: Dual
function of MyD88 in RAS signaling and inflammation, leading to
mouse and human cell transformation. J Clin Invest. 120:3663–3667.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Watanabe S, Yamaguchi S, Fujii N, Eguchi
N, Katsuta H, Sugishima S, Iwasaka T and Kaku T: Nuclear
Co-expression of p21 and p27 induced effective cell-cycle arrest in
T24 cells treated with BCG. Cytotechnology. 71:219–229. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang XT, Chai ZB, Zou JR, Wang HX, Wang
Y, Zheng YB, Wu H and Liu CY: PADI3 induces cell cycle arrest via
the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in
colon cancer. Cancer Biol Med. 16:729–742. 2019. View Article : Google Scholar : PubMed/NCBI
|
